Dr. Chris Stomberg and Dr. Alexandre Carbonnel will participate in a workshop that will help pharmaceutical companies and lawyers navigate the burgeoning antitrust risks in the EU. The free workshop will be held on 30 November at the Les Salons de l’Hôtel des Arts e Mètiers in Paris.
Most recent pharmaceutical antitrust cases in the EU have focused on practices which attempt to prevent market entry, in particular by generics, through pay-for-delay settlements or misuse of the patent system. There has been much less focus on agreements between originators and generics allowing generics to enter prior to patent expiry and outside litigation. However, pharma companies are sometimes concerned that such agreements may be viewed as anticompetitive by competition authorities, for instance, if they restrict competition beyond patent expiry.
Dr. Stomberg and Dr. Carbonnel will be joined by Olivier Fréget, Founding Partner of Fréget Glaser and Associés, Hélène Messmer, Rapporteure Permanente with the Autorité de la Concurrence, and Gabriele Venskaityte, Case Handler at DG Comp in a conversation exploring the legal framework for assessing early entry agreements in the pharmaceutical sector and the role of litigation and arbitration in resolving disputes.